JP2024109616A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024109616A5 JP2024109616A5 JP2024074184A JP2024074184A JP2024109616A5 JP 2024109616 A5 JP2024109616 A5 JP 2024109616A5 JP 2024074184 A JP2024074184 A JP 2024074184A JP 2024074184 A JP2024074184 A JP 2024074184A JP 2024109616 A5 JP2024109616 A5 JP 2024109616A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cxcr4
- gpcrx
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762607876P | 2017-12-19 | 2017-12-19 | |
| US62/607,876 | 2017-12-19 | ||
| US201862679598P | 2018-06-01 | 2018-06-01 | |
| US62/679,598 | 2018-06-01 | ||
| US201862732946P | 2018-09-18 | 2018-09-18 | |
| US62/732,946 | 2018-09-18 | ||
| PCT/KR2018/016166 WO2019124951A1 (en) | 2017-12-19 | 2018-12-18 | Gpcr heteromer inhibitors and uses thereof |
| JP2020535043A JP7517986B2 (ja) | 2017-12-19 | 2018-12-18 | Gpcrヘテロマー阻害剤及びその用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535043A Division JP7517986B2 (ja) | 2017-12-19 | 2018-12-18 | Gpcrヘテロマー阻害剤及びその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024109616A JP2024109616A (ja) | 2024-08-14 |
| JP2024109616A5 true JP2024109616A5 (cg-RX-API-DMAC7.html) | 2024-12-03 |
| JP7818648B2 JP7818648B2 (ja) | 2026-02-20 |
Family
ID=66813757
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535043A Active JP7517986B2 (ja) | 2017-12-19 | 2018-12-18 | Gpcrヘテロマー阻害剤及びその用途 |
| JP2024074184A Active JP7818648B2 (ja) | 2017-12-19 | 2024-05-01 | Gpcrヘテロマー阻害剤及びその用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020535043A Active JP7517986B2 (ja) | 2017-12-19 | 2018-12-18 | Gpcrヘテロマー阻害剤及びその用途 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10709763B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3900712A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7517986B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20200103018A (cg-RX-API-DMAC7.html) |
| CN (1) | CN111741752A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018388302B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112020012075A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3086337A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI818938B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019124951A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200103018A (ko) | 2017-12-19 | 2020-09-01 | 주식회사 지피씨알 | Gpcr 헤테로머 억제제 및 이의 용도 |
| JP7849948B2 (ja) | 2018-03-05 | 2026-04-22 | テオン セラピューティクス,インク. | アデノシン受容体アンタゴニストおよびその使用 |
| KR20220078526A (ko) * | 2019-03-06 | 2022-06-10 | 인메드 파마슈티컬스 인코포레이티드 | 이종 시스템에서 테르페노이드 또는 칸나비노이드의 생합성을 위한 조성물 및 방법 |
| KR20210156849A (ko) * | 2019-05-17 | 2021-12-27 | 주식회사 지피씨알 | Gpcr 헤테로머 저해제들 및 이의 용도 |
| KR102268983B1 (ko) * | 2019-09-11 | 2021-06-24 | 경북대학교 산학협력단 | 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도 |
| CN110755431B (zh) * | 2019-11-08 | 2023-02-28 | 暨南大学 | 地氯雷他定在制备抗肝癌药物中的应用 |
| JPWO2022025168A1 (cg-RX-API-DMAC7.html) * | 2020-07-30 | 2022-02-03 | ||
| EP4196611A1 (en) | 2020-08-15 | 2023-06-21 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity in subjects having variant nucleic acid molecules encoding calcitonin receptor (calcr) |
| CN112807425A (zh) * | 2021-01-14 | 2021-05-18 | 南方医科大学深圳医院 | 一种tTIM融合蛋白疫苗、制备方法及应用 |
| EP4306655A4 (en) * | 2021-08-04 | 2024-08-21 | Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd | PRIMER-PROBE SET, KIT AND DETECTION METHOD FOR DETECTING HUMAN HISTAMINE RECEPTOR HRH1 mRNA |
| CN114574580B (zh) * | 2022-02-14 | 2022-11-29 | 山东大学 | 靶向a2br联合化疗在三阴性乳腺癌治疗中的应用 |
| WO2023211779A1 (en) * | 2022-04-25 | 2023-11-02 | Kallyope, Inc. | Treatment of headache disorders with nk3 modulators |
| AU2023285050A1 (en) * | 2022-06-10 | 2025-01-23 | Gpcr Therapeutics, Inc. | Gpcr inhibitors and uses thereof |
| CN114891742B (zh) * | 2022-06-23 | 2024-06-04 | 杭州中赢生物医疗科技有限公司 | 一种强杀伤性nk细胞的培养基及体外扩增方法 |
| CN116298305B (zh) * | 2023-01-03 | 2024-05-28 | 郑州大学 | 一种抗nt5c1a自身抗体检测方法及体外诊断试剂盒 |
| KR20260011143A (ko) | 2023-04-18 | 2026-01-22 | 칼리오페, 인크. | Nk3 조정제 및 이의 용도 |
| AU2024334309A1 (en) * | 2023-08-30 | 2026-03-05 | Josephine Cardarelli | Gpcr inhibitors and uses thereof |
| CN119345201B (zh) * | 2024-12-25 | 2025-03-18 | 中国人民解放军总医院第三医学中心 | 治疗tfe3基因重排性肾细胞癌的药物或药物组合物及用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998000538A2 (en) | 1996-07-01 | 1998-01-08 | Biosignal Inc. | Peptides and peptidomimetic compounds affecting the activity of g-protein-coupled receptors by altering receptor oligomerization |
| AU3249997A (en) | 1996-07-01 | 1998-01-21 | Biosignal Inc. | Method of assaying compounds which affect the activity of g protein-coupled receptors based on measurement of receptor oligomerization |
| US6855807B1 (en) | 1999-06-16 | 2005-02-15 | New York University | Heterodimeric opioid G-protein coupled receptors |
| US20010053848A1 (en) | 2000-03-10 | 2001-12-20 | Patel Yogesh C. | Hetero-oligomeric G protein-coupled receptors as novel drug targets |
| CN102302493B (zh) * | 2001-07-31 | 2015-08-12 | 健赞股份有限公司 | 活化祖细胞/干细胞的方法 |
| EP1625159B1 (en) | 2003-05-20 | 2011-03-02 | The University Court Of The University Of Glasgow | Materials and methods relating to g-protein coupled receptor oligomers |
| WO2005103721A1 (en) * | 2004-04-20 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4) |
| CA2640087A1 (en) * | 2006-01-25 | 2007-08-02 | Mount Sinai School Of Medicine | Methods and compositions for modulating the mobilization of stem cells |
| US20090028832A1 (en) * | 2006-08-10 | 2009-01-29 | Chung Leland F | Compositions and methods for targeted tumor therapy |
| US9212226B2 (en) * | 2008-05-16 | 2015-12-15 | Ablynx N.V. | Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same |
| WO2010002468A1 (en) | 2008-07-01 | 2010-01-07 | The Trustees Of Columbia University In The City Of New York | A functional complementation assay for defined gpcr oligomers |
| FR2949156B1 (fr) | 2009-08-13 | 2016-04-15 | Cis-Bio Int | Methode de determination de la liaison d'un compose donne a un recepteur membranaire |
| WO2011091435A2 (en) | 2010-01-25 | 2011-07-28 | Mount Sinai School Of Medicine | Methods of treating liver disease |
| JP2011168567A (ja) * | 2010-02-22 | 2011-09-01 | Kyoto Univ | 再発癌の予防または治療用医薬 |
| KR101029972B1 (ko) | 2010-06-18 | 2011-04-20 | 서울대학교산학협력단 | 바이러스 벡터를 이용하여 단백질의 상호작용을 측정하는 방법 |
| WO2012047339A2 (en) * | 2010-06-28 | 2012-04-12 | The General Hospital Corporation | Anti-cxcr4 as a sensitizer to cancer therapeutics |
| US9267934B2 (en) * | 2010-10-26 | 2016-02-23 | University Of South Alabama | Methods and compositions for ameliorating pancreatic cancer |
| MX371455B (es) * | 2013-08-02 | 2020-01-28 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco. |
| EP3030322A2 (en) * | 2013-08-05 | 2016-06-15 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| CN103536594A (zh) * | 2013-10-21 | 2014-01-29 | 江苏亚虹医药科技有限公司 | G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途 |
| WO2015095973A1 (en) | 2013-12-23 | 2015-07-02 | Université de Montréal | Systems and methods for the monitoring of protein complex formation in cells |
| DK3242685T3 (da) * | 2015-01-09 | 2022-07-25 | Adalta Ltd | Cxcr4-bindende molekyler |
| WO2017020128A1 (en) * | 2015-08-03 | 2017-02-09 | Université de Montréal | Markers for acute myeloid leukemias with core binding factor rearrangements and other genetic subtypes and uses thereof |
| KR20200103018A (ko) | 2017-12-19 | 2020-09-01 | 주식회사 지피씨알 | Gpcr 헤테로머 억제제 및 이의 용도 |
-
2018
- 2018-12-18 KR KR1020207019080A patent/KR20200103018A/ko not_active Ceased
- 2018-12-18 KR KR1020267002674A patent/KR20260035212A/ko active Pending
- 2018-12-18 CA CA3086337A patent/CA3086337A1/en active Pending
- 2018-12-18 JP JP2020535043A patent/JP7517986B2/ja active Active
- 2018-12-18 WO PCT/KR2018/016166 patent/WO2019124951A1/en not_active Ceased
- 2018-12-18 BR BR112020012075-8A patent/BR112020012075A2/pt active Search and Examination
- 2018-12-18 EP EP21174644.1A patent/EP3900712A1/en active Pending
- 2018-12-18 CN CN201880089801.6A patent/CN111741752A/zh active Pending
- 2018-12-18 AU AU2018388302A patent/AU2018388302B2/en active Active
- 2018-12-18 TW TW107145764A patent/TWI818938B/zh active
- 2018-12-18 US US16/224,450 patent/US10709763B2/en active Active
- 2018-12-18 EP EP18892135.7A patent/EP3727371A4/en active Pending
-
2020
- 2020-05-27 US US16/885,196 patent/US11857600B2/en active Active
-
2021
- 2021-04-16 US US17/233,359 patent/US20210268069A1/en not_active Abandoned
-
2024
- 2024-05-01 JP JP2024074184A patent/JP7818648B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021507925A5 (cg-RX-API-DMAC7.html) | ||
| Magnaghi et al. | Afatinib is a new therapeutic approach in chordoma with a unique ability to target EGFR and brachyury | |
| Nakagawa et al. | Immunohistochemical KIT (CD117) expression in thymic epithelial tumors | |
| Cheng et al. | Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma | |
| Pernis et al. | Interleukin 4 signals through two related pathways. | |
| MX2013010581A (es) | Receptor del factor de crecimiento de fibroblastos (fgfr) y ligandos del mismo como biomarcadores para cancer de mama en sujetos hr positivos. | |
| JP2009092508A (ja) | リウマチ治療剤の効果の予測方法 | |
| ES2663843T3 (es) | Utilización de la proteína olfactomedina-4 (OLFM4) en el diagnóstico del cáncer colorrectal | |
| US20150361504A1 (en) | Biomarker for predicting response of cll to treatment with a btk inhibitor | |
| McLeskey et al. | Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. | |
| Sabah et al. | The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining | |
| Sequeira et al. | The oral and skin pathergy test | |
| Lee et al. | Genetic analysis of ovarian microcystic stromal tumor | |
| KR20230147136A (ko) | Raf 억제제와 mek 억제제의 조합 | |
| Hornick et al. | The significance of KIT (CD117) in gastrointestinal stromal tumors | |
| Koyama et al. | Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment | |
| Kang et al. | Extragastrointestinal stromal tumor presenting as a scrotal mass: an unusual case | |
| US10426777B2 (en) | Methods used to treat cancer | |
| Potti et al. | Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma | |
| JP2008515459A (ja) | オートクライン成長因子受容体および方法 | |
| Rolfes et al. | 421TiP OPTImaL: Optimisation of treatment for patients with low stage triple-negative breast cancer with high stromal tumor-infiltrating lymphocytes | |
| Khrais et al. | Primary cutaneous anaplastic large cell lymphoma with gastric metastasis | |
| Zhang et al. | 1422P Identification and validation of novel microenvironment-based immune molecular subgroups of esophageal squamous-cell carcinoma | |
| Ananthaswamy et al. | Correlation between Ha-ras gene amplification and spontaneous metastasis in NIH 3T3 cells transfected with genomic DNA from human skin cancers | |
| EP4715383A1 (en) | Test strip for testing analyte in sample |